Related Experiment Video

Updated: Aug 30, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Tolerability and treatment compliance with angiotensin II receptor antagonists

Giuseppe Mancia1, Gino Seravalle, Guido Grassi

  • 1Clinica Medica, Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Università Milano-Bicocca, Monza, Milan, Italy. giuseppe.mancia@unimib.it

American Journal of Hypertension
|December 4, 2003
PubMed

Insights

Hypertension management has improved cardiovascular outcomes, but blood pressure control remains suboptimal in many patients. New antihypertensive drugs like angiotensin II receptor antagonists offer better tolerability and compliance.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension-related cardiovascular risk is reducible through blood pressure (BP) lowering.
  • Antihypertensive drug treatment significantly decreases cardiovascular events and complications.
  • Current population-level BP control is suboptimal, with less than 25% of treated patients achieving target BP <140/90 mm Hg.

Purpose of the Study:

  • To review the current status of BP control in treated hypertensive individuals.
  • To examine factors contributing to inadequate BP control, focusing on patient compliance.
  • To evaluate the tolerability and compliance of angiotensin II receptor antagonists (ARBs).

Main Methods:

  • Review of existing studies and intervention trials on hypertension management.
  • Analysis of factors influencing treatment adherence and drug side effects.
  • Assessment of the efficacy and safety profiles of ARBs.

Main Results:

  • Despite evidence of improved cardiovascular risk reduction, optimal BP control is not widespread.
  • Inadequate compliance, drug intolerance, and underutilization of combination therapy hinder BP control.
  • ARBs demonstrate a favorable tolerability and compliance profile.

Conclusions:

  • Improving BP control in hypertensive patients is crucial for reducing cardiovascular morbidity and mortality.
  • Addressing compliance issues and optimizing drug selection, including ARBs, are key strategies.
  • ARBs represent a promising therapeutic option for enhancing treatment adherence and achieving BP targets.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...